Literature DB >> 14735405

Impact of drug-resistant Mycobacterium tuberculosis on treatment outcome of culture-positive cases of tuberculosis in the Archangel oblast, Russia, in 1999.

O S Toungoussova1, N I Nizovtseva, A O Mariandyshev, D A Caugant, P Sandven, G Bjune.   

Abstract

The objective of this study was to evaluate the outcome of treatment of culture-positive cases of tuberculosis registered in Archangel, Russia, in 1999, and to analyse the influence of Mycobacterium tuberculosis drug resistance on treatment outcome. The outcome of tuberculosis treatment was evaluated for 235 new and 61 previously treated culture-positive cases diagnosed in 1999. Of the 235 new cases, there were 150 (63.8%) cases of treatment completion, 20 (8.5%) cases of treatment failure, 29 (12.3%) cases of death during treatment, and 29 (12.3%) cases in which the patient failed to pick up medications for at least 2 consecutive months. The outcome in 7 (3%) cases was unknown, as the patients were transferred outside the oblast region. Among the 61 previously treated cases, the rate of treatment completion was low (26.2%), and rates of treatment failure (23%) and failure to pick up medications for at least 2 consecutive months (29.5%) were high. The relation between the susceptibility pattern of the infecting strain as determined by the Bactec method and tuberculosis treatment outcome was analysed for 76 patients. The majority (69%) of patients infected with drug-susceptible strains was cured. A large proportion (58.8%) of patients infected with Mycobacterium tuberculosis resistant to more than two drugs did not respond to treatment, i.e. the treatment failed or the patients died. The high rates of death (16.7%) and failure (66.7%) among patients infected with multidrug-resistant strains illustrate the negative impact of multidrug resistance on the outcome of tuberculosis treatment. Pan-resistance was significantly associated with treatment failure (P<0.001). The spread of resistant Mycobacterium tuberculosis has a serious negative impact on the outcome of tuberculosis treatment in Archangel, Russia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14735405     DOI: 10.1007/s10096-003-1080-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Problems and solutions for the Stop TB partnership.

Authors:  S M Blower; C L Daley
Journal:  Lancet Infect Dis       Date:  2002-06       Impact factor: 25.071

2.  Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.

Authors:  R Singla; N Al-Sharif; M O Al-Sayegh; M M Osman; M A Shaikh
Journal:  Int J Tuberc Lung Dis       Date:  2002-07       Impact factor: 2.373

3.  Guidelines for surveillance of drug resistance in tuberculosis. WHO Geneva/IUATLD Paris. International Union Against Tuberculosis and Lung Disease.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  1998-01       Impact factor: 2.373

4.  Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study.

Authors:  M Flament-Saillour; J Robert; V Jarlier; J Grosset
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

5.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.

Authors:  M A Espinal; S J Kim; P G Suarez; K M Kam; A G Khomenko; G B Migliori; J Baéz; A Kochi; C Dye; M C Raviglione
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

6.  Drug-resistant tuberculosis in Korea, 1994.

Authors:  S J Kim; G H Bai; Y P Hong
Journal:  Int J Tuberc Lung Dis       Date:  1997-08       Impact factor: 2.373

7.  Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.

Authors:  S Toungoussova; D A Caugant; P Sandven; A O Mariandyshev; G Bjune
Journal:  Int J Tuberc Lung Dis       Date:  2002-05       Impact factor: 2.373

8.  Treatment outcome of relapse and defaulter pulmonary tuberculosis patients.

Authors:  T Sevim; G Ataç; G Güngör; I Törün; E Aksoy; K Tahaoglu
Journal:  Int J Tuberc Lung Dis       Date:  2002-04       Impact factor: 2.373

9.  Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Lea Pehme; Solomon Ghebremichael; Tuija Koivula; Sven E Hoffner; Marika Mikelsaar
Journal:  Clin Infect Dis       Date:  2002-06-14       Impact factor: 9.079

10.  Application of new technology to the detection, identification, and antimicrobial susceptibility testing of mycobacteria.

Authors:  M A Pfaller
Journal:  Am J Clin Pathol       Date:  1994-03       Impact factor: 2.493

View more
  4 in total

1.  Characterization of Tunisian Mycobacterium tuberculosis rifampin-resistant clinical isolates.

Authors:  Alya Soudani; Sondess Hadjfredj; Mériem Zribi; Afef Masmoudi; Taieb Messaoud; Hanéne Tiouri; Chedlia Fendri
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

2.  Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Authors:  Edward C Jones-López; Irene Ayakaka; Jonathan Levin; Nancy Reilly; Francis Mumbowa; Scott Dryden-Peterson; Grace Nyakoojo; Kevin Fennelly; Beth Temple; Susan Nakubulwa; Moses L Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Jerrold J Ellner; Peter G Smith; Roy D Mugerwa
Journal:  PLoS Med       Date:  2011-03-15       Impact factor: 11.069

3.  Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia.

Authors:  Belete Getahun; Gobena Ameni; Sibhatu Biadgilign; Girmay Medhin
Journal:  BMC Infect Dis       Date:  2011-05-16       Impact factor: 3.090

Review 4.  Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature.

Authors:  Tingting Jiang; Xiang-Sheng Chen
Journal:  Int J Environ Res Public Health       Date:  2020-02-21       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.